Lacosamide Oral Solution
Product Images NDC 71921-411

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lacosamide Oral Solution (NDC 71921-411). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Florida Pharmaceutical Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide-carton (Lacosamide Carton)

Label for Lacosamide Oral Solution, USP 10 mg/mL, a 200 mL prescription oral solution. The label includes dosage strength, storage instructions between 20° to 25°C, a warning to discard unused product six months after opening, and a note for pharmacists to dispense the Medication Guide. Manufactured by Indoco Remedies Ltd. and labeled for Florida Pharmaceutical Products, LLC.*

FDA Label Image

Lacosamide-container (Lacosamide Container)

Label for Lacosamide Oral Solution USP 10 mg/mL, a 200 mL oral solution by Florida Pharmaceutical Products, LLC. The label includes storage instructions, dosage notice, a pharmacist attention note, and manufacturer information for Indoco Remedies Ltd. It also shows the NDC 71921-411 and space for lot and expiration dates.*

FDA Label Image

Lacosamide-fig-1 (Lacosamide Fig 1)

This bar chart displays the median percent reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose across three separate studies comparing placebo and Lacosamide treatments. The x-axis shows placebo and various Lacosamide doses (mg/day) with sample sizes, while the y-axis represents percent seizure reduction from 0% to 45%. Lacosamide groups consistently demonstrate greater median seizure reduction compared to placebo, with statistical significance indicated.*

FDA Label Image

Lacosamide-fig-2 (Lacosamide Fig 2)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4' plotting responder rate (equal to or greater) on the vertical axis against percent of patients on the horizontal axis. It compares placebo and three dosages of Lacosamide (200 mg/day, 400 mg/day, 600 mg/day) with corresponding patient sample sizes, showing improvement and worsening responder rates.*

FDA Label Image

Lacosamide-fig-3 (Lacosamide Fig 3)

A Kaplan-Meier survival curve graph comparing the proportion of patients over time (days) between placebo and Lacosamide groups in a clinical study. The graph includes data points and lines for both placebo (N=121) and Lacosamide (N=118), showing statistical analysis results including a p-value of 0.001, hazard ratio, and confidence interval.*

FDA Label Image

Lacosamide -structure (Lacosamide Structure)

Chemical structure of lacosamide, the active ingredient in Lacosamide Oral Solution 10 mg/mL. The diagram shows the molecular arrangement of atoms and bonds characteristic of lacosamide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.